For the first time in years, the cost of some of the most in demand medications in the world is starting to come down—and quickly.
In the past week, Health Canada has approved two companies to produce generic versions of Ozempic. At the same time, increased competition is beginning to influence pricing for newer medications like Mounjaro (also known as Zepbound).
For patients, this is a meaningful shift. But it also makes the landscape more complex. The lowest listed price is not the full story.
These medications have transformed how we approach metabolic health. Originally developed for type 2 diabetes, they are now widely used to support weight loss, improve insulin resistance, and reduce long term cardiovascular risk. In addition, emerging research suggests additional benefits, including a reduced risk of conditions such as Alzheimer’s disease.
They belong to a class of drugs known as GLP-1 receptor agonists which help regulate blood sugar, reduce appetite, and improve energy metabolism. Mounjaro goes one step further by targeting both GLP-1 and GIP receptors, which is why many patients experience greater weight loss and improved tolerability.
Until recently, the biggest barrier for many patients has been cost.
What Are Patients Actually Paying Today?
Historically, Ozempic has ranged from approximately $220 to $300 per month in Canada, depending on dose and pharmacy pricing. Mounjaro, as a newer medication, has typically ranged from $400 to $550 per month.
While some patients have insurance coverage, the reality is that most private drug plans, as well as BC Pharmacare, only cover GLP-1 medications if very specific clinical thresholds are met. These criteria are often restrictive, and many patients who would benefit do not qualify under their plans.
As a result, a large proportion of patients are left paying the full cost out of pocket if they want access to these therapies. This has been one of the primary reasons cost has limited broader use.
Generic Ozempic (Semaglutide): A Turning Point for Access and Affordability
That is now changing.
With generic Ozempic approved, initial pricing is expected to be approximately $100 per month. Over time, that price will likely fall further as additional manufacturers are approved and competition increases.
Regardless of where the final price settles, the introduction of generic Ozempic is expected to put sustained downward pressure on pricing across all GLP-1 medications. This represents a meaningful improvement in access and a structural shift in the market.
It’s Not Just Ozempic: The Bigger Pricing Shift
The impact of generic semaglutide extends well beyond Ozempic.
In anticipation of increased competition, Mounjaro has already reduced its pricing by approximately 30%. In addition, its patient support program has been expanded and made more accessible, further lowering the effective cost for many patients.
The conversation is no longer about list price alone, but the true monthly cost after thoughtful prescribing and available support programs.
How Patients Are Paying Less for Mounjaro
At Lifespan Medical, we focus on making these therapies more financially sustainable for our patients. Two strategies can significantly reduce the cost of Mounjaro.
The first is patient support programs, which can reduce monthly costs by approximately 15%.
The second is how the medication is packaged and priced across different pen sizes.
Mounjaro is delivered through pre-filled pens that contain different total amounts of medication, typically intended for weekly use over about a month. Importantly, higher-volume pens are often priced very similarly to lower-volume versions, despite containing up to six times more medication.
With appropriate medical guidance, some patients may be prescribed a higher-volume pen and instructed on how to use it in a way that aligns with their individualized dosing plan. This can allow the pen to last longer (up to 6 times longer) which significantly reduces the effective monthly cost.
This approach must always be directed and supervised by a qualified medical professional to ensure safe and appropriate dosing. Patients should not attempt to adjust dosing on their own.
When combined, these two strategies, patient support programs and thoughtful prescribing of higher-volume pens, can reduce the effective cost of Mounjaro to as low as $80 per month. Depending on the dose prescribed, this represents savings of up to 80% off the original list price.
When Price Isn’t the Whole Story
This is where the comparison becomes more relevant.
If generic Ozempic is initially priced at approximately $100 per month and Mounjaro can be accessed at a price as low as $80 per month (using appropriate dosing strategies), the decision shifts from price to which medication has the better outcome with least side effects.
In clinical practice, Mounjaro has demonstrated greater average weight loss and stronger improvements in blood sugar control. As well, many patients who experienced gastrointestinal side effects on other GLP-1 medications such as Ozempic have tended to tolerate Mounjaro much better.
In my experience, most patients do well on Mounjaro, with relatively few experiencing significant side effects when dosing is introduced and adjusted appropriately.
How to Make the Right Choice
This is a rare and exciting moment where access, affordability, and effectiveness for GLP-1 medications are all improving at the same time.
Generic Ozempic is expanding access by driving down the price of all GLP-1 medications. At the same time, with the right strategy and clinical guidance, patients may be able to access newer therapies like Mounjaro at a similar or even lower effective cost.
At Lifespan Medical, our focus is on helping patients navigate these decisions safely and effectively—helping them select the right medication, optimizing dosing under medical supervision, and building a plan that is both clinically effective and financially sustainable.
If you are considering a GLP-1 medication, or wondering whether you are on the most appropriate and cost effective option, this may be an ideal time to reassess.